Congress, White House Eye SCHIP Compromises

BY ALICIA AULT
Associate Editor, Practice Trends

Congress and the Bush administration headed back to the negotiating table in mid-October after the House of Representatives failed to override President Bush's veto of the State Children's Health Insurance Program reauthorization legislation.

The House voted 273-156 to override the president's SCHIP veto, but that was 10 votes short of the needed two-thirds majority. The vote was split down party lines, with 229 Democrats and 44 Republicans voting in favor of override, and 154 Republicans and 2 Democrats voting against.

SCHIP expired on Sept. 30, but a continuing resolution ensures that the program is funded through Nov. 16.

House Speaker Nancy Pelosi (D-Calif.) said that she aims to bring a new version of the SCHIP legislation to the floor for a vote ahead of that deadline, Ron Pollack, executive director of Families USA, said in an interview. Mr. Pollack predicted that compromises would be crafted around the issues that concern the White House, which he calls "myths." Among those: that the law would cover children in families earning up to $83,000 a year, and that illegal immigrants would be eligible for coverage. These issues led a majority of House Republicans to vote in line with President Bush, he said.

About 6 million children are currently enrolled in SCHIP. The congressional proposal would have increased funding by about $7 billion a year, adding as many as 4 million children to the SCHIP rolls.

The American College of Physicians said it would push for passage of a new bill that would ensure coverage for those additional children. "The current SCHIP formula does not go far enough," said Dr. David C. Dale, ACP president, in a statement.

Rep. Charles Rangel (D-N.Y.) blasted the Bush administration as being out of touch with the American people. "It is appalling that the administration would declare victory after denying health care to 10 million of the neediest children in America," he said in a statement.

The White House said in a statement that it had appointed a team to negotiate with Congress to make sure at least 500,000 children who currently are eligible for SCHIP, but not receiving benefits, would be enrolled in the program. "If enrolling these children requires more than the 20% funding increase proposed by the President, we will work with Congress to find the necessary money," the White House said. ■

ENDO PHARMACEUTICALS

LIDODERM®
(Lidocaine Patch 5%)

Brief Summary (For full Prescribing Information and Patient Information, refer to package insert.)

INDICATIONS AND USAGE
LIDODERM is indicated for relief of pain associated with post-herpetic neuralgia. It should be applied only to intact skin.

CONTRAINDICATIONS
LIDODERM is contraindicated in patients with a known history of sensitivity to *local* anesthetics of the amide type, or to any other component of the product.

WARNINGS
Accidental Exposure in Children
Even a *used* LIDODERM patch contains a large amount of lidocaine (at least 665 mg). The potential exists for a small child or a pet to suffer serious adverse effects from chewing or ingesting a new or used LIDODERM patch, although the risk with this formulation has not been evaluated. It is important for patients to **store and dispose of LIDODERM out of the reach of children, pets, and others**. (See HANDLING AND DISPOSAL)

Excessive Dosing
Excessive dosing by applying LIDODERM to larger areas or for longer than the recommended wearing time could result in increased absorption of lidocaine and high blood concentrations, leading to serious adverse effects (see ADVERSE REACTIONS, Systemic Reactions). Lidocaine toxicity could be expected at lidocaine blood concentrations above 5 µg/mL. The blood concentration of lidocaine is determined by the rate of systemic absorption and elimination. Longer duration of application, application of more than the recommended number of patches, smaller patients, or impaired elimination may all contribute to increasing the blood concentration of lidocaine. With recommended dosing of LIDODERM, the average peak blood concentration is about 0.13 µg/mL, but concentrations higher than 0.25 µg/mL have been observed in some individuals.

PRECAUTIONS
General
Hepatic Disease: Patients with severe hepatic disease are at greater risk of developing toxic blood concentrations of lidocaine, because of their inability to metabolize lidocaine normally.

Allergic Reactions: Patients allergic to para aminobenzoic acid derivatives (procaine, tetracaine, benzocaine, etc.) have not shown cross sensitivity to lidocaine. However, LIDODERM should be used with caution in patients with a history of drug sensitivities, especially if the etiologic agent is uncertain.

Non-intact Skin: Application to broken or inflamed skin, although not tested, may result in higher blood concentrations of lidocaine from increased absorption. LIDODERM is only recommended for use on intact skin.

Eye Exposure: The contact of LIDODERM with eyes, although not studied, should be avoided based on the findings of severe eye irritation with the use of similar products in animals. If eye contact occurs, immediately wash out the eye with water or saline and protect the eye until sensation returns.

Drug Interactions
Antiarrhythmic Drugs: LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic.

Local Anesthetics: When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.

Carcinogenesis, Mutagenesis, Impairment of Fertility
Carcinogenesis: A minor metabolite, 2, 6-xylidine, has been found to be carcinogenic in rats. The blood concentration of this metabolite is negligible following application of LIDODERM.

Mutagenesis: Lidocaine HCl is not mutagenic in Salmonella/mammalian microsome test nor clastogenic in chromosome aberration assay with human lymphocytes and mouse micronucleus test.

Impairment of Fertility: The effect of LIDODERM on fertility has not been studied.

Pregnancy
Teratogenic Effects: Pregnancy Category B. LIDODERM (lidocaine patch 5%) has not been studied in pregnancy. Reproduction studies with lidocaine have been performed in rats at doses up to 30 mg/kg subcutaneously and have revealed no evidence of harm to the fetus due to lidocaine. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, LIDODERM should be used during pregnancy only if clearly needed.

Labor and Delivery
LIDODERM has not been studied in labor and delivery. Lidocaine is not contraindicated in labor and delivery. Should LIDODERM be used concomitantly with other products containing lidocaine, total doses contributed by all formulations must be considered.

Nursing Mothers
LIDODERM has not been studied in nursing mothers. Lidocaine is excreted in human milk, and the milk: plasma ratio of lidocaine is 0.4. Caution should be exercised when LIDODERM is administered to a nursing woman.

Pediatric Use
Safety and effectiveness in pediatric patients have not been established.

ADVERSE REACTIONS
Application Site Reactions
During or immediately after treatment with LIDODERM (lidocaine patch 5%), the skin at the site of application may develop blisters, bruising, burning sensation, depigmentation, dermatitis, discoloration, edema, erythema, exfoliation, irritation, papules, petechia, pruritus, vesicles, or may be the locus of abnormal sensation. These reactions are generally mild and transient, resolving spontaneously within a few minutes to hours.

Allergic Reactions
Allergic and anaphylactoid reactions associated with lidocaine, although rare, can occur. They are characterized by angioedema, bronchospasm, dermatitis, dyspnea, hypersensitivity, laryngospasm, pruritus, shock, and urticaria. If they occur, they should be managed by conventional means. The detection of sensitivity by skin testing is of doubtful value.

Other Adverse Events
Due to the nature and limitation of spontaneous reports in postmarketing surveillance, causality has not been established for additional reported adverse events including:

Asthenia, confusion, disorientation, dizziness, headache, hyperesthesia, hypoesthesia, lightheadedness, metallic taste, nausea, nervousness, pain exacerbated, paresthesia, somnolence, taste alteration, vomiting, visual disturbances such as blurred vision, flushing, tinnitus, and tremor.

Systemic (Dose-Related) Reactions
Systemic adverse reactions following appropriate use of LIDODERM are unlikely, due to the small dose absorbed (see CLINICAL PHARMACOLOGY, Pharmacokinetics). Systemic adverse effects of lidocaine are similar in nature to those observed with other amide local anesthetic agents, including CNS excitation and/or depression (light headedness, nervousness, apprehension, euphoria, confusion, dizziness, drowsiness, tinnitus, blurred or double vision, vomiting, sensations of heat, cold, or numbness, twitching, tremors, convulsions, unconsciousness, respiratory depression, and arrest). Excitatory CNS reactions may be brief or not occur at all, in which case the first manifestation may be drowsiness merging into unconsciousness. Cardiovascular manifestations may include bradycardia, hypotension, and cardiovascular collapse leading to arrest.

OVERDOSAGE
Lidocaine overdose from cutaneous absorption is rare, but could occur. If there is any suspicion of lidocaine overdose (see ADVERSE REACTIONS, Systemic Reactions), drug blood concentration should be checked. The management of overdose includes close monitoring, supportive care, and symptomatic treatment. Dialysis is of negligible value in the treatment of acute overdose with lidocaine.

In the absence of massive topical overdose or oral ingestion, evaluation of symptoms of toxicity should include consideration of other etiologies for the clinical effects, or overdosage from other sources of lidocaine or other local anesthetics.

The oral LD_{50} of lidocaine HCl is 459 (346-773) mg/kg (as the salt) in non-fasted female rats and 214 (159-324) mg/kg (as the salt) in fasted female rats, which are equivalent to roughly 4000 mg and 2000 mg, respectively, in a 60 to 70 kg man based on the equivalent surface area dosage conversion factors between species.

DOSAGE AND ADMINISTRATION
Apply LIDODERM to intact skin to cover the most painful area. Apply up to three patches, only once for up to 12 hours within a 24-hour period. Patches may be cut into smaller sizes with scissors prior to removal of the release liner. (See HANDLING AND DISPOSAL) Clothing may be worn over the area of application. Smaller areas of treatment are recommended in a debilitated patient, or a patient with impaired elimination.

If irritation or a burning sensation occurs during application, remove the patch (es) and do not reapply until the irritation subsides.

When LIDODERM is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all formulations must be considered.

HANDLING AND DISPOSAL
Hands should be washed after the handling of LIDODERM, and eye contact with LIDODERM should be avoided. Do not store patch outside the sealed envelope. Apply immediately after removal from the protective envelope. Fold used patches so that the adhesive side sticks to itself and safely discard used patches or pieces of cut patches where children and pets cannot get to them. LIDODERM should be kept out of the reach of children.

Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F). [See USP Controlled Room Temperature].

Manufactured for:
Endo Pharmaceuticals Inc.
Chadds Ford, Pennsylvania 19317

Manufactured by:
Teikoku Seiyaku Co., Ltd.
Sanbonmatsu, Kagawa 769 2695
Japan

LIDODERM® is a Registered Trademark of Hind Health Care, Inc.

Copyright© Endo Pharmaceuticals Inc. 2007

Rev. April, 2007
6524-10 E1

References: 1. Lidoderm Prescribing Information. Chadds Ford, Pa: Endo Pharmaceuticals Inc; 2006. **2.** Galer BS. Advances in the treatment of postherpetic neuralgia: the topical lidocaine patch. *Today's Therapeutic Trends.* 2000; 18:1-20. **3.** Argoff CE. Targeted topical peripheral analgesics in the management of pain. *Curr Pain Headache Rep.* 2003;7:34-38. **4.** Rowbotham MC, Davies PS, Verkempinck C, Galer BS. Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. *Pain.* 1996;65:39-44. **5.** Data on file. **6.** Galer BS, Jensen MP, Ma T, Davies PS, Rowbotham MC. The lidocaine patch 5% effectively treats all neuropathic *pain qualities: results* of a randomized, double-blind, vehicle-controlled, 3-week efficacy study with use of the neuropathic pain scale. *Clin J Pain.* 2002;18:297-301.

R_x only

LIDODERM® is a registered trademark of Hind Health Care, Inc.

ENDO PHARMACEUTICALS

CHADDS FORD, PENNSYLVANIA 19317 © 2007 Endo Pharmaceuticals LD-1486B/OCTOBER 2007 1-800-462-ENDO www.lidoderm.com

STATEMENT OF OWNERSHIP, MANAGEMENT AND CIRCULATION (Required by 39 U.S.C. 3685). 1. Publication title: INTERNAL MEDICINE NEWS. 2. Publication No. 1097-8690. 3. Filing date: October 1, 2007. 4. Issue frequency: Semimonthly. 5. No. of issues published annually: 24. 6. Annual subscription price: $115.00. 7. Complete mailing address of known office of publication: International Medical News Group, 60 Columbia Rd., Bldg. B, Morristown, NJ 07960. 8. Complete mailing address of headquarters or general business office of publisher: International Medical News Group, 60 Columbia Rd., Bldg. B, Morristown, NJ 07960. 9. Full names and complete mailing addresses of Publisher, Editor, and Managing Editor: President, IMNG, Alan J. Imhoff, IMNG, 60 Columbia Rd., Bldg. B, Morristown, NJ 07960; Excutive Director, Editorial, Mary Jo M. Dales, IMNG, 5635 Fishers Lane, Suite 6000, Rockville, MD 20852; Editor, Calvin Pierce, IMNG, 5635 Fishers Lane, Suite 6000, Rockville, MD 20852. 10. Owner: Elsevier Inc. Stock is owned 100% by Harcourt Inc., 6277 Sea Harbor Dr., Orlando, FL 32887. 11. Known bondholders, mortgagees, and other security holders owning or holding 1 percent or more of total amount of bonds, mortgages or other securities: None. 12. For completion by nonprofit organizations authorized to mail at special rates. 13. Publication name: INTERNAL MEDICINE NEWS. 14. Issue date for circulation data below: September 15, 2007. 15. Extent and nature of circulation: Average no. copies each issue during preceding 12 months: a. Total number of copies (net press run) 120,479; b. Legitimate paid and/or requested distribution (by mail and outside the mail) (1) Individual paid/requested mail subscriptions stated on PS Form 3541 60,198 (2) Copies requested by employers for distribution to employees by name or position stated on PS Form 3541 0. (3) Sales through dealers and carriers, street vendors, counter sales, and other paid or requested distribution outside the USPS 0, (4) Requested copies distributed by other mail classes through the USPS 0; c. Total paid and/or requested circulation 60,198; d. Nonrequested distribution (by mail and outside the mail) (1) Nonrequested copies stated on PS Form 3541 60,043; (2) Nonrequested copies distributed through the USPS by other classes of mail 0; (3) Nonrequested copies distributed outside the mail 0; e. Total nonrequested distribution 60,043; f. Total distribution 120,241; g. Copies not distributed 238; h. Total 120,479; i. Percent paid and/or requested circulation 50%. Actual no. copies of single issue published nearest to filing date a. Total numbers of copies (net press run) 120,219; b. Legitimate paid and/or requested distribution (by mail and outside the mail) (1) Individual paid/requested mail subscriptions stated on PS Form 3541 64,925; (2) Copies requested by employers for distribution to employees by name or position stated on PS Form 3541 0; (3) Sales through dealers and carriers, street vendors, counter sales, and other paid or requested distribution outside the USPS 0; (4) Requested copies distributed by other mail classes through the USPS 0; c. Total paid and/or requested circulation 64,925; d. Nonrequested distribution (1) Nonrequested copies stated on PS Form 3541 55,037; (2) Nonrequested copies distributed through the USPS by other classes of mail 0; (3) Nonrequested copies distributed outside the mail 0; e. Total nonrequested distribution 55,037; f. Total distribution 119,962; g. Copies not distributed 257; h. Total 120,219; i. Percent paid and/or requested circulation 54% 16. This Statement of Ownership will be printed in the November 1, 2007 issue of this publication. 17. Signature and title of Editor, Publisher, Business Manager, or Owner: Alan J. Imhoff, President, IMNG.